Korsana Biosciences vs Oramed Pharmaceuticals
Korsana Biosciences and Oramed Pharmaceuticals are similar in size: $2.1m and $2.0m of revenue in their latest fiscal years. Oramed Pharmaceuticals grew faster (49.3% against 3.7%). Oramed Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 3202.5% against -170.1%. Korsana Biosciences carries less debt relative to equity (0.0% against 0.3%).
| Latest fiscal year | Korsana BiosciencesKRSA, 2025 | Oramed PharmaceuticalsORMP, 2025 |
|---|---|---|
| Revenue | $2.1m | $2.0m |
| Revenue growth | 3.7% | 49.3% |
| Net income | −$3.5m | $64.0m |
| Operating margin | -239.8% | -754.4% |
| Net margin | -170.1% | 3202.5% |
| Return on equity | -39.3% | 35.2% |
| Free cash flow | −$3.3m | −$9.2m |
| Cash | $3.2m | $45.9m |
| Total debt | $0 | $652,000 |
| Debt to equity | 0.0% | 0.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $4.7m |
| Employees | — | — |
| Market value | $135m | $165m |
| Price vs our value range | — | — |
| Moat score | — | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 4 sales |